ArticleFrontiers in pharmacology2025
Spectrum mining of immune checkpoint inhibitor-related cutaneous toxicities and analysis of associated factors based on FAERS.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AI-enabled precision prediction and proactive management of cutaneous toxicities in cancer immunoradiotherapy (ICI+RT).Frontiers in oncology · 2026Review
- Case Report: Rapid recurrence of psoriasiform dermatitis upon sequential anti-PD-1 therapy with pembrolizumab and tislelizumab with 3-year follow-up.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The study sought to delineate the cutaneous toxicity spectrum of immune-checkpoint inhibitors by using the US FDA Adverse Event Reporting System, and to qualify association with other immune-related adverse events (irAEs). Methods: Disproportionality analyses relied on Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN) and proportional reporting ratio (PRR). Univariable and multivariable logistic regression were then applied to identify other irAEs that predicted irAE-Cutaneous. Results: (1) Most reports involved men aged >65 years. (2) Toxicity spectrum and outcomes: Most reports involved men over 65. Five drugs showed positive signals via the three algorithms. Immune-mediated dermatitis had the strongest signals across all. Ipilimumab strongly linked to vitiligo (ROR = 45.531); nivolumab (ROR = 9.656) and pembrolizumab (ROR = 8.376) to psoriasiform dermatitis; tislelizumab to acquired epidermolysis bullosa (ROR = 8.376). Rash and pruritus were common but weakly specific. Pembrolizumab had highest RORs for toxic epidermal necrolysis (ROR = 4.384) and Stevens-Johnson syndrome (ROR = 3.599). Nivolumab had most severe event reports, then pembrolizumab. (3) Association with other irAEs: Univariable analysis linked pneumonitis, hyperthyroidism, myositis, fatigue, hypothyroidism to skin irAEs (all P < 0.05); multivariable analysis found hyperthyroidism, myositis, fatigue, hypothyroidism as independent predictors (P < 0.05). Conclusion: Distinct toxicity spectra of each drug were observed. Hyperthyroidism, myositis, fatigue and hypothyroidism independently increase the likelihood of irAE-Cutaneous.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.